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Abstract
The purpose of this chapter is to outline key considerations for increasing access to clini-
cal trials for people with cancer living in rural and remote locations, and outline the 
contribution of tele-health models to facilitate study activity across rural and remote loca-
tions. Regional and rural group of the Clinical Oncology Society of Australia (COSA), the 
peak multidisciplinary cancer clinician body in Australia, has developed the Australasian 
Teletrial Model in collaboration with its stakeholders to improve rural access to clinical 
trials. Benefits of this model are not limited to regional, rural and remote systems. This 
model has the potential to connect larger centres even within the same city and improve 
the rate of recruitment of highly specialised clinical trials, including rare cancer trials. 
This model has been developed in consideration of the requirements for the proper con-
duct of clinical trials ensuring the protection of the rights and safety of trial participants 
and quality data for the demonstration of safe and efficacious cancer treatments. Ethical 
and safe conduct of clinical trials using this model requires that the following aspects are 
considered and addressed by implementation plans.
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1. Introduction
Access to specialist cancer care services is a significant issue faced by residents of rural, 
remote, indigenous and some regional communities in countries with large rural and outer 
metropolitan populations [1]. For these communities, the lack of access to specialist services 
may be due to a lack of specialist oncologists locally, limited scope of practice of other rural 
health professionals and/or overall rural workforce shortages. Poor access to such special-
ised health care services could be one of the contributors to the disparity in survival and 
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disease-related outcomes that exist between metropolitan and non-metropolitan patients 
[2–5], although the authors acknowledge this issue as complex and may also relate to other 
factors such as behavioural or cultural factors.
It is recommended by leading authorities, such as the National Comprehensive Cancer 
Network (www.nccn.org) and Cancer Research UK [6], that support for the provision of 
clinical trials to people diagnosed with cancer is a core component of providing optimal can-
cer care through specialist cancer centres, hospitals and other treatment facilities. Indeed, in 
many cases such guidelines recommend participation in clinical trials as the best option for 
many cancer patients.
Clinical trials offered to people diagnosed with cancer may include new and experimental 
drug therapies or imaging technologies, minimally invasive diagnostic or surgical techniques, 
or supportive care interventions. However, as with access to specialist care, patients living 
outside of major metropolitan centres face many barriers in accessing clinical trials. Barriers to 
participation include the limited availability of trial sites closer to home and the increased cost 
and inconvenience of travel to major centres where the trials are taking place [7, 8].
While it may be reasonable to establish clinical trials units in large regional cancer treatment 
centres, the logistics of maintaining a suitably trained workforce and undertaking the ethical 
and regulatory responsibilities of clinical trials may be difficult in smaller rural and regional 
sites with limited resources and low patient numbers.
Tele-oncology models of care have been shown to satisfy many specialist health care needs of 
rural and regional patients in countries with large rural populations [1]. Using tele-oncology 
models, many cancer centres have been able to facilitate the administration of complex che-
motherapy in rural and regional areas [9–11]. Around the world, such centres have imple-
mented safe and successful tele-oncology models that are acceptable to patients, families and 
health professionals, saved money for health service provision and enhanced the capabilities 
of rural health systems in oncology services to provide cancer care [10, 12–17]. In addition, 
cancer services can be delivered to rural patients closer to home in a timely manner [18]. Tele-
oncology models of care may outline a system-level intervention to address issues of equity 
and access to clinical trials. For example, adopting this model would enable rural and regional 
sites with limited resources to provide access to Phase III comparative effectiveness studies 
and potentially trials of new and novel therapies for the local population.
This document outlines a feasible and effective tele-health strategy to increase access to clinical 
trials closer to home, while at the same time ensuring the proper conduct of cancer clinical trials.
1.1. Overview of established clinic and treatment models of tele-oncology in Australia 
and globally
Similar to most of the specialist tele-health models around the world, the Townsville tele-
oncology [15] model enables medical oncologists from Townsville, Australia to provide their 
services to rural sites, using traditional videoconferencing technology or web-based systems 
(Figure 1). At larger rural centres, rurally-based doctors, chemotherapy-competent nurses 
and allied health workers accompany patients during tele-consultations. At other rural sites, 
patients are accompanied by either a doctor or a nurse for post-treatment reviews, toxicity 
reviews or follow-up visit(s) tele-consultations [12].
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When a patient is assessed as fit for chemotherapy or targeted therapy, medical oncologists 
write the care plan and send the prescriptions to rural sites where chemotherapy is given by 
chemotherapy-competent nurses. Where electronic systems are available, care plans are made 
and approved online. For oral chemotherapy, authority scripts are sent by medical oncolo-
gists to patients, rural hospitals or the local pharmacy after appropriate education by medical 
oncologists, nurses or pharmacists. Prior to the clinic, informed consent for participation in 
the tele-oncology clinic is obtained from the patients.
1.2. Remote chemotherapy supervision model
While the models mentioned above are largely medical tele-health models, models such as the 
Queensland Remote Chemotherapy Supervision (QReCS) model [19] enables rural generalist 
nurses to administer chemotherapy at rural sites with the support of the rural generalist doctors 
and pharmacists, under the supervision of medical oncologists and chemotherapy-competent 
nurses from larger centres using tele-medicine and tele-nursing respectively (Figure 2) [20].
Figure 1. A model of a rural specialist unit with specialist support via tele-medicine model of care. Sabesan et al. EJCC, 
2015.
Figure 2. Remote chemotherapy supervision model.
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2. Core principles of the tele-trial model
The core principles of the tele-trial model are as follows:
1. To increase accessibility to trials thereby reducing the need for people with cancer to travel 
to larger centres to attend study-related visits and undertake study-related procedures. 
Using tele-oncology models, there is an opportunity for patients from rural or regional 
sites to be recruited, consented, and treated, and to attend follow-up visits—a hub-and-
spoke approach between a primary trial site and a satellite site. The roles and responsibili-
ties for each site need to be clearly defined at the outset of each trial and appropriately 
contracted (Figure 3).
2. To develop collaboration and networking between regional/rural and metropolitan cen-
tres and between tertiary centres even within the same metropolitan setting with the aim 
of delivering greater engagement in research activity, improving adherence to evidence-
based practice, improve the rate of recruitment of patients into clinical trials, reducing the 
disparity in cancer outcomes for geographically dispersed populations, building clinical 
trial capacity, and providing trial-related training.
3. To articulate the relationship between the primary site and satellite site as a trial cluster. 
The trial cluster co-ordinates the trial across multiple sites including a primary site and one 
or more satellite site(s), ideally through streamlined trial processes (Figure 4). A trial clus-
ter may exist in the following settings: (a) larger metropolitan centres as primary sites with 
other metropolitan centres as satellites even within the same city; (b) larger metropolitan 
centres or large regional centres as primary sites with smaller regional or rural sites as 
satellites; or (c) larger regional centres as primary sites with metropolitan centres as satel-
lites in an attempt to improve the capabilities and community profile of regional centres.
Figure 3. Australasian teletrial model. Adapted from Sabesan and Zalcberg [21].
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2.1. Anticipated benefits
Similar to tele-health models for delivering routine cancer care, there are a range of benefits 
associated with conducting clinical trials using tele-health strategies. Modern informatics 
supporting technological advancements in communication enable a greater depth of reach to 
more Australians. Notably the tele-trial model has the potential to make clinical trials acces-
sible to people with cancer from rural and remote centres closer to home. Increasing acces-
sibility for increased participant recruitment may also improve collaboration and networking 
between rural and metropolitan centres, provide workforce development, facilitate engage-
ment in research activity for improved adherence with guideline recommended care and 
reduce the disparity in cancer outcomes for geographically dispersed populations.
There is a second related benefit of the model for Australia’s geographic reality, and compara-
tively small population for which tele-trials may provide a useful solution. This benefit relates 
to the complexity and innate molecular and phenotypic heterogeneity of cancer. That is, any one 
tumour type is actually made of multiple discrete subgroups. Hence, trials requiring the eligible 
population to have a similar tumour subtype in order to compare two different interventions are 
more and more difficult to conduct. Increasingly, these studies involve numerous centres around 
Australia or indeed internationally. The corollary of such an observation is that individual cen-
tres, even large tertiary referral centres will only see a very small number of patients whose 
tumour fits the eligibility criteria for these studies in any one year. As the cost of establishing 
and maintaining the infrastructure to open poorly recruiting studies is so high, such centres are 
becoming increasingly reluctant to open these studies in the first place. Consequently, these stud-
ies recruit even fewer patients overall than might reasonably be expected because the only trial 
site(s) recruiting to one of these studies is geographically distant from the potential participant.
Another advantage is workforce development. Exposure to, and involvement in research 
provides professional development opportunities through collaboration with leading  clinical 
Figure 4. A tele-trial cluster.
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researchers. This may have flow-on benefits for improved access to trials and improved qual-
ity of care. There are also advantages for Australia to develop a more flexible approach to the 
conduct of trials; given our relatively small population and geographic barriers to recruitment. 
Recruiting specific patient cohorts is an ever-present challenge. Without multisite collabora-
tion, Australia is less attractive to international trial Sponsors, which limits the availability of 
experimental, life-saving treatments. Developing these clinical trial networks through models 
like this tele-trial concept, we can better promote our capacity to support a wider range of 
trials.
Tele-trials offer the unique opportunity to impact this inevitable cascade of circumstances that 
compound the difficulties of defining new treatments for so many cancers in the modern era 
of molecular characterisation of cancer across regional and rural Australia.
2.2. Anticipated costs and threats
While the benefits discussed above have positive flow on effects on patient care and the 
Australian Health system as a whole, system improvement using this model is unlikely to 
be achieved without added cost for the sponsors (including increased site visits, medication 
transport cost to satellites, etc.), hospitals and governments (increased workforce, techno-
logical and pharmacy infrastructure). Benefits of improved rural access to clinical trials and 
enhanced rate of recruitment can offset those extra costs. Reforms on remote monitoring, site 
accreditation, ethical, governance and contractual processes are required at a system level to 
reduce financial and human resource cost.
Geographic isolation due to distance may cause several problems including workforce sta-
bility, transporting and handling of medications and devices, access to source documents 
and communication between sites which can be mitigated by implementing the processes 
outlined in this document.
3. Requirements for implementation of the tele-trial model
Satellite sites (regional, rural or metropolitan) would vary in their capability to conduct tri-
als based on resources and prior experience. Based on the capabilities of the satellite sites, 
primary sites may delegate to the satellite sites some or all aspect of trials, in agreement with 
the sponsors and satellites.
3.1. Selection of satellite sites and suitable trials
Site feasibility assessments may have to consider the capability of the whole cluster and 
potential satellite sites are indicated during the site feasibility process. This informs the trial 
Sponsor of the referral relationship between the primary site and satellite sites within the clus-
ter. The cluster may include hospitals within the same region, network or local health district 
or hospitals in other regions, networks and local health districts. Once the primary site is cho-
sen, the acceptance of the satellite sites by a trial Sponsor will depend on the prior experience 
of the satellite site in conducting clinical trials, the complexity of the trial, and the medical, 
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nursing, allied health, pathology and pharmacy research capabilities. Site capacity and trial 
complexity will determine the ability of the site to conduct trial-related activities at the satel-
lite site and will be assessed by the Sponsor at the time of site selection. It is not anticipated 
the satellite site will undertake all trial-related activities. Satellite sites that have established 
trial capabilities are able to take part in complex protocols from the outset. At sites that have 
no or limited experience in delivering clinical trials, a staged approach may allow for gradual 
building of clinical trials capacity from simple to more complex trials.
3.1.1. Accreditation of satellites
For sites that have not taken part in clinical trials previously, as required under current prac-
tice, it is likely that the Sponsor may wish to perform a site visit. The Sponsor may also wish 
to delegate this responsibility to the primary site.
3.1.2. Supervision plan
Some registration bodies require that the primary site Principal Investigator (PI) take respon-
sibility for overall supervision of the trial across a cluster. Tele-health offers a unique oppor-
tunity for direct supervision of patient management. A supervision plan agreed between the 
primary and satellite sites and the Sponsor needs to be developed and formalised at the outset 
of a trial. The supervision plan may include, but not be limited to, details on joint consulta-
tions using tele-health, collation and monitoring of documents, frequency of joint trial meet-
ings across a cluster (with minutes of these meetings) and any site visits performed by the PI.
3.1.3. Site visits
While the travel by staff and patients is reduced as the result of this model, Sponsors may 
wish to undertake site visits for accreditation and monitoring purposes, unless remote moni-
toring is agreed by the Sponsor and source documents are available at the primary site.
3.2. Workforce: roles and responsibilities
The workforce requirements of current tele-health models could be extended to the tele-trial 
model. While larger rural and regional centres may have resident or visiting medical oncolo-
gists, oncology clinicians and trial nurses, satellite sites may have limited specialised services. 
Under the current tele-health models, urban specialists at a primary site provide their services 
using videoconferencing. Service delivery is supported and facilitated by doctors, nurses and 
allied health professionals at a satellite site. The nature of support to and by the rural health 
professionals would be determined by the complexity of the trial and the clinical capabilities 
at the site [22, 23]. The delegated responsibilities would need to be agreed by the Sponsor, 
clearly documented within the master site file and trial-related training records provided 
before this delegation could occur.
Defining roles and allocating specific responsibilities to staff within a cluster can ensure the 
safe and efficient conduct of clinical trials. The satellite team would need to take part in the 
Investigator Meeting & Study Initiation Visit so that they are fully aware of the requirements 
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for compliance with the Investigational Brochure (IB), study protocol and the importance of 
these required processes. Tele-health technologies offer the opportunity to conduct investiga-
tor meetings and study initiation visits across geographically dispersed clusters. This is par-
ticularly important for reporting and managing adverse events and serious adverse events, 
and ensuring that patient reported outcomes are completed in a timely manner without 
excessive missing data.
3.3. Good clinical practice
All clinical trials involving Clinical Trial of Investigational Medicinal Products (CTIMPs) 
must be conducted according to the principles of International Conference on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and 
local laws for Good Clinical Practice (GCP). ICH and GCP requirements, local laws and regu-
lations and the Sponsors’ protocol and company requirements as outlined in the Australian 
legislative requirements applying to prescription medicines are contained in the Therapeutic 
Goods Act 1989 and the Therapeutic Goods Regulations 1990.
3.4. Roles and responsibilities of trial site staff
Prior experience of staff and capabilities of the satellite sites would determine the roles of the 
satellite trial staff. PI may delegate some or all of the trial-related processes to the satellite site 
staff, in agreement with the sponsor and satellite staff. It is important that roles and responsi-
bilities are agreed and formalised at the outset.
3.4.1. Primary investigator at primary sites
Some registration bodies require that the PI is responsible for overall supervision of the trial, 
including satellite sites. Therefore, it is important to develop a supervision plan including cover 
for holidays and unexpected leave at the outset of a trial and incorporate this into the contract.
1. Participate in trial consultations with satellite site medical officers via tele-health if required.
2. Take part in the consenting and recruitment process remotely or on-site as required via 
tele-health.
3. Communication with satellite investigators regarding protocol revisions,
4. Provide oversight of SAE reporting, ensuring satellite sites provide source documents and 
reports as required.
5. Be available to consult on the management of Serious Adverse Events and adverse events 
(SAE/AEs) as required.
6. Maintain a delegation log for all research staff at both primary site and satellite sites.
7. Ensure all staff at both the Primary and Satellite Site are trained in the trial specific activi-
ties delegated to each.
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8. Develop arrangements for radiology and pathology reviews and for engagement with oth-
er clinicians including genetic counsellors, other specialists and allied health professionals, 
as dictated by trial protocols, across a cluster.
3.4.2. Satellite site investigators
Satellite site medical officers will be the local contact for trial-related matters within a satellite 
unless the PI and the primary site agree to take this responsibility. Depending on the prior 
experience of satellite site investigators and satellite capabilities, the PI may delegate some or 
all of the trial-related responsibilities to the satellite site investigators:
1. Conduct joint trial visits with primary sites when required by the trial Sponsor.
2. Satellite sites would require monitoring visits to review source documents that are not 
entered into an electronic medical record (EMR) system or shared between the satellite site 
and primary site.
3. Undertake ICH-GCP accreditation and training on the study protocol.
4. Take part in the consenting process, perform and document physical assessments.
5. Manage, store and dispense CTIMP if required and accredited to do so.
6. Undertake activities related to study follow-up.
7. Timely communication and management of AEs and SAEs and study reporting in collabo-
ration with primary sites.
8. Develop arrangements in collaboration with the PI for radiology and pathology reviews 
and for engagement with other clinicians including genetic counsellors, other specialists 
and allied health professionals, as dictated by trial protocols, within their site.
9. Develop plans for local contacts during periods of cover for holidays and unexpected leave.
3.4.3. Trial co-ordinators
Trial co-ordinators at primary sites act as a contact for coordinators at both the primary and 
satellite sites.
1. Coordinate the study and monitor progress across the cluster.
2. Collate and coordinate documentation from satellite sites including the preparation of 
CRFs.
3. Identify staff changes and initiate appropriate training.
4. Conduct trial meetings by including satellite sites.
5. Manage the regulatory processes and reporting requirements to the trial Sponsor, and hu-
man research ethics committees as required.
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3.4.4. Pharmacy and pharmacy facilities
Trial Sponsors may elect to deliver CTIMP directly to the site, dispensing the CTIMP and 
maintain drug accountability documentation at the site. Sponsors may delegate this respon-
sibility to the primary sites. This requires the primary and satellites sites to work together 
collaboratively. Both the primary and the satellite site(s) would need to ensure that adequate 
documentation is in place to allow full drug accountability and be suitably qualified to under-
take the following:
1. The primary site pharmacist is responsible for overall service provision in collaboration 
with satellites, i.e. receipt of the IP, storage and handling, dispatch to satellite or trial par-
ticipant, reconciliation and communicating the management of IP with the satellite site. 
The primary site pharmacist will be the first point of contact when trials involving CTIMPs 
are under consideration by the primary site.
2. Designated pharmacy staff providing a clinical trial service must be adequately qualified, 
trained and experienced to assume clinical research responsibilities and should be able to 
provide up-to-date GCP training records.
3. The pharmacy must hold training records and signature logs for those staff involved in a 
clinical trial in the pharmacy department. These will be held at the site and should include 
all staff involved at either the primary site or satellite sites. These records may also be held 
in a central location and should be readily available for inspection if required.
4. Appropriate facilities should be available before agreeing to support a clinical trial par-
ticularly one involving radiopharmaceuticals or Advanced Therapy Medicinal Products 
(ATMPs) such as gene therapy and cell therapy. The pharmacy lead site for clinical trials 
should liaise with, and seek advice from, satellite sites with experience in handling these 
types of products.
5. The institution (pharmacy department) is required to hold a GMP licence as per the TGA 
annotated guidelines annex 13.
6. Manufacturing must be performed to GMP and release performed by a Qualified Person—
in certain circumstances labelling may be performed at a site but the facilities have to be 
certified and reach GMP standards etc.
7. If the satellite site does not have access to a local GMP qualified facility they would not be 
able to participate in trials with this requirement.
8. Pharmacies should have facilities that allow for CTIMPs to be stored separately from nor-
mal pharmacy stock in an area with access restricted to pharmacy staff. Licensed products 
used as CTIMPs do not have to be stored separately as long as there is a process in place 
to ensure traceability.
9. CTIMPs that are returned by patients or expired should be stored separately from unused 
CTIMPs. Quarantined medication should be clearly identified and segregated from work-
ing stock.
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10. Regular temperature monitoring of CTIMP storage facilities should be undertaken and 
records maintained for both primary and satellite sites. All CTIMP storage areas should 
be fitted with calibrated temperature monitoring devices that record minimum and maxi-
mum temperatures, with a robust system to alert staff if the temperature falls outside of 
the specified range. The temperature monitoring devices should have a valid calibration 
certificate which is maintained for reference. The pharmacy should have written proce-
dures in place for the actions to be taken when the storage conditions are outside of the 
specified range.
11. Pharmacies should have an approved destruction policy that outlines the process for 
destroying; although some Sponsors may require unused, expired or returned CTIMP 
study medication to be returned to a Sponsor nominated central licensed facility for 
destruction.
12. Pharmacy files will be kept by the primary site and where requested, may develop ad-
ditional accountability logs and files for satellite site usage.
13. Suitable archiving facilities will be required for pharmacy trial files. The system used for 
archiving must allow for prompt retrieval of any pharmacy study file or of non-study 
specific documentation (such as pharmacy standard operating procedures, original phar-
macy temperature monitoring records and training records of pharmacy staff).
14. Pharmacy should receive funding for providing a clinical trial service. This funding 
should reflect the workload and cover costs involved and is separate to the prescription 
charge.
15. Procedures for unblinding must be made available to the satellite site in the case of an 
emergency.
The patient compliance with taking the medication will be monitored by the dispensing phar-
macy, nursing and medical officers. During joint consultations, primary site clinicians can 
also reiterate to patients.
3.4.5. Pathology and radiology
Pathology and radiology requirements are dealt with at the feasibility questionnaire stage 
and arrangements agreed by Sponsors. Biopsy and biomarker and pharmacodynamic studies 
may require onsite centrifuge, processing and storage. If the satellite site does not have these 
capabilities, private pathology could be used and considered subcontractors or agents of the 
primary site in agreement with the Sponsor. Similar arrangement could be made for radiol-
ogy requirements. For sites that have never participated in trials, the Sponsor may wish to 
conduct a site visit to assess these aspects.
3.5. Training
Training requirements are the same for both the primary and satellite site staff involved in 
clinical trials within a cluster.
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3.5.1. Training for individual staff
All investigators and trial staff at each site are required to have undertaken GCP training 
and certification. Individual staff members should ensure GCP competence is commensurate 
with their roles and responsibilities in relation to the study protocol and the management of 
CTIMPs. Whilst it may be the case that some staff carry out trial-related tasks that are part of 
their normal role, they should be certified in the principles of GCP. A mentorship program 
would be of benefit where staff from the satellite sites have the opportunity to observe and 
have hands on experience at the primary site is one such example. Primary and satellite staff 
training is required to ensure that staff are competent to participate in the conduct of, or for 
providing the supporting and delegated activities of, a clinical trial. Both the primary and 
satellite sites must retain training records and signature logs for those staff involved in the 
clinical trial. These records should be readily available for inspection if required. GCP training 
can be accessed through the Australian Clinical Trials website: https://www.australianclini-
caltrials.gov.au/researchers/good-clinical-practice-gcp-australia
3.5.2. Site initiation and trial update
Site initiation meetings and site staff training on the trial protocol for primary and satellite 
sites in a cluster could be undertaken via videoconferencing across a large geographical area. 
Site initiation meetings could also be used to reiterate the roles and responsibilities of staff 
across all sites. Joint consultations and regular trial meetings are also useful forums for dis-
cussing trial-related matters and updates.
3.6. Technology and support
A web-based system or videoconferencing equipment are required for interactive consulta-
tions. Availability of the electronic medical record (EMR) would enable seamless sharing of 
clinical data between sites. However, where the EMR is not available, source documents will 
need to be provided to the primary sites for data verification and trial monitoring purposes 
unless the Sponsor wishes to conduct trial monitoring visits themselves. While a tele-health 
approach may support the visit process both the primary and satellite sites need to understand 
the critical need for reliable source documents. In cases of technical failure, a secondary source 
of web-based technology should be available to ensure continuity of clinical encounters.
3.7. Participant screening and recruitment
It is expected that all processes and activities related to recruitment are coordinated by the pri-
mary site in communication with the satellite site. Satellite sites that have adequate resources 
could assist with screening and referral of patients for recruitment. Doctors, nurses and trial 
coordinators are able to identify patients, provide trial-related information and notify the 
primary sites, prior to participant consent being obtained.
NB: It is important to note that the National Statement has special requirements when enroll-
ing special populations for example indigenous members of the community therefore sites 
need to ensure these requirements are met where appropriate.
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3.8. Obtaining participant consent
Patients from satellite sites are screened and recruited and provide consent for trial participa-
tion in collaboration with doctors and nurses at primary and satellite sites using video-link or 
on-site in a process approved by the Sponsor and the HREC.
3.8.1. Options for obtaining consent
The process for obtaining consent remotely via tele-health or onsite would be reviewed by the 
Sponsor and approved by the HREC. Satellite sites can be delegated responsibility to obtain 
informed consent.
For sites that do not have prior experience in clinical trials, it is important that the PI is directly 
involved in the trial consent process. In this option, the participants and the satellite site inves-
tigator sign the consent form, observed by an investigator at the primary site. This process is 
documented concurrently at both the primary site and satellite sites. At sites that have prior 
experience in trials, the satellite site investigator may be delegated to complete the consent 
process onsite. A copy of this final consent form can be given to the participant and stored 
in the medical record and in the primary trial site file. Mode of transfer for these documents 
(fax, emails and/or post) needs to be agreed by the Sponsor according to their privacy policies.
3.9. Medication handling
Sponsors may prefer to deliver CTIMP or devices directly to primary and satellite sites to reduce 
the cost of medication transport. At the request of the Sponsor, the primary site pharmacy may 
transfer clinical trial medication for administration or collection to satellite sites. Medications may 
include the investigational product and/or non-investigational medications related to the clinical 
trial. The following Sponsor approved medication could be managed in the following way:
a. Medication is dispensed and/or prepared according to protocol and accountability logs 
are completed.
b. Medication is sealed in a non-transparent bag clearly labelled with the patient details.
c. An acknowledgement of receipt form and a copy of the prescription are attached to the 
outside of the bag of medication.
d. The bag of medication is placed into a suitable container (e.g. box or padded envelope) and 
labelled and packaged for transport.
e. Cold pack and temperature monitor should be included for medication requiring refriger-
ated storage being transported from the primary site.
f. As per IB/Sponsor or manufacturers instruction.
g. Completed CTIMP containers being returned to the primary site are not required to be 
temperature-monitored. However, if a temperature-monitoring device is supplied by the 
Sponsor, the primary pharmacy will include it with the parcel with instructions to be fol-
lowed by satellite site.
Access to Clinical Trials Closer to Home Using Tele-health
http://dx.doi.org/10.5772/intechopen.70205
169
h. The pharmacy at the receiving satellite site is contacted by telephone to notify them of the 
delivery.
i. The courier service is contacted to arrange suitable pick-up/delivery.
j. The faxed signed copy of the Acknowledgement of Receipt from the satellite site is filed 
with the original prescription in the primary site Pharmacy folder.
k. In the event that the Acknowledgement of Receipt is not received by the primary site 
Pharmacy within 48 hours, the satellite site is contacted to check that the parcel has been 
received.
3.10. Managing and reporting adverse events (AEs) and serious adverse events (SAEs)
3.10.1. Management at routine clinics
During planned trial consultations, the history of AEs and SAEs is obtained. Clinical trial staff 
needs to be aware that drug intervention studies will require minimum reporting times and 
the occurrence of AEs/SAEs are to be reported to the primary site in the usual within 24 hour 
plan by any satellite staff, medical practitioner, nurse or data manager. SAEs are managed 
according to the protocol and documented in the EMR or medical charts by medical special-
ists/medical officers at satellite sites. If EMR is not available, certified copies of the source 
documents may be required and sent to the primary sites for monitoring purposes. Mode 
of transfer for these documents (fax, emails and/or post) needs to be agreed by the Sponsor 
according to their privacy policies. Upon notification of an AE or SAE, the trial coordinator 
at primary or satellite site will report SAEs to the Sponsor and follow the local procedure 
for documenting and reporting adverse events to the approving Human Research Ethics 
Committee (HREC) and local site governance office.
Roles of trial staff regarding this aspect of care need to be outlined in the site responsibility 
form, agreed upon by both primary and satellite sites and the Sponsor and incorporated into 
the contracts. Engagement with other specialists either via tele-health or onsite needs to be 
finalised according to the trial protocol. This is important for managing immune-related and 
unusual side effects of medications including trial medications.
3.10.2. Additional consideration for unplanned presentation during and after hours
In cases of presentation to hospital between medical consultations, the on-site investiga-
tor needs to be contacted by emergency staff who in turn will notify the primary site staff 
within 24 hours. Trial coordinators at the primary site and medical specialists are informed 
by any satellite staff who is the first to become aware and a joint review may be initiated using 
videoconferencing.
A ‘trial patient alert’ process would be useful for alerting the emergency staff or general prac-
titioners that a patient is on a trial so that on-call specialists can be contacted. The name of the 
trial and contact details for the PI at both the primary and satellite sites needs to be included.
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Patients and their families need to be educated of the need for seeking urgent medical atten-
tion and reporting to the primary and/or satellite site staff of their concerns. Patients could 
also be given letters or brochures for communication with clinicians in an emergency situa-
tion. Not all situations may be able to be managed at the satellite site. Inter-hospital transfers 
may be required in consultation between primary and satellite medical officers in some cases.
3.11. Patient reported outcomes (PROs)
Some trials will include PROs, including quality of life endpoints, usually as secondary end-
points, but sometimes as primary. It is a matter of equity that rural and remote patients have 
the opportunity to self-report aspects of their health and quality of life as specified in the trial 
protocol.
PROs are typically assessed with questionnaires, either handed out to trial participants by the 
research nurse or completed online. The specific questionnaires, mode(s) of administration, 
and timing relative to recruitment and treatment need to be followed as per trial protocols. 
It is also important to develop mechanisms to minimise missing data as far as possible and 
record reasons for missing data, so patient engagement is essential.
Many trials groups have reported success of centralised monitoring systems for maintaining 
high PRO completion rates. Staff should have access to ongoing training and written guidance 
and understand the importance of PROs.
3.12. Documentation and reporting
During trial consultations, a detailed patient history including the documentation of AEs 
and SAEs is obtained by doctors at primary or satellite sites or at both sites simultaneously. 
Results of investigations are available online at most centres. If results are not available online, 
the primary site will ensure certified copies are provided by the satellite site.
Physical examination may be performed by the doctor at the satellite site with or without 
observation by the primary site doctor and as per ICG-GCP the PI can only delegate to those 
with the necessary experience, training and qualifications. When joint medical consultations 
are conducted via tele-health, clinical encounters are documented at the site with the delega-
tion to perform the specific study-related activity. If EMR is not available, certified copies of 
the source documents may be required and sent to the primary sites for monitoring purposes. 
Mode of transfer for these documents (fax, emails and/or post) needs to be agreed by the 
Sponsor according to their privacy policies.
3.13. Financial considerations
Consideration also needs to be given to how satellite sites will be reimbursed for undertaking 
trial specific procedures (e.g. blood tests; radiology procedures, etc.).
There are administrative efficiencies if the co-ordination of invoicing or journal transfers for 
trial-related expenses at satellites sites are coordinated by the primary site. Generally most of 
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the expenses related to staff will be covered by existing work contracts and funding mecha-
nisms that exist for routine operations. Remuneration of sites for trial-related activities should 
equate to the proportion of work the site undertakes and should be negotiated between 
Sponsor, primary and satellite sites at the outset. Primary sites need to be renumerated for 
coordination of trial activities and preparation of regulatory documentations across clusters.
3.14. Regulatory considerations
Many of the regulatory aspects of clinical trials are governed by local and state jurisdictions 
and are therefore beyond the scope of this document. It is important to engage with health 
service executives, ethics committees and research governance officers to expedite approval 
processes within clusters. However, a simplified and streamlined approach at state and 
national level may reduce the cost and expedite the approval processes.
It is recommended that the primary site takes the responsibility for preparation and submis-
sion of documents related to ethics, contracts and site-specific assessment forms (SSAs) in 
order to streamline and expedite the trial approval processes. Contractual, ethical and gov-
ernance processes can be expedited when common standards and strong collaboration are 
established between primary and satellite sites within clusters.
It is prudent for clinicians or cancer centre managers who wish to participate in this model to 
get the support of their managers and chief executive officers especially in developing trial 
clusters between centres located within other health service districts and states so that gover-
nance and contract processes can be streamlined.
3.15. Indemnity, insurance and clinical trial agreements
Primary sites and the Sponsor assume responsibility for ensuring that criteria for safe care are 
met by all sites within a cluster. When undertaking investigator lead trials, both the primary 
and satellite are indemnified as per each state and territory health department provision. For 
industry-sponsored studies the indemnity is provided by the trial Sponsor (https://medicine-
saustralia.com.au/policy/clinical-trials/indemity-and-compensation-guidelines/).
The Sponsor of a clinical trial takes overall responsibility for the conduct of the trial, including 
protocol design and the investigational product.
Agreements between sites within a cluster could be in the form of formal contracts, or over-
arching agreements such as Service Level Agreements (SLA). This matter needs to be solved 
at the local level between health services or at the state level through research and governance 
offices in collaboration with the Sponsors.
4. Conclusion and recommendations
System improvement using this model is unlikely to be achieved without added cost and addi-
tional resources for the Sponsors, hospitals and governments. Simplification and streamlin-
ing of site accreditation and selection processes, monitoring requirements, ethics, governance 
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and contractual matters are needed to reduce cost and workload, and to expedite approval 
processes.
4.1. Recommendations
1. Adoption of tele-trial models such as the Australasian Teletrial model as part of standard 
practice by cooperative trial groups, industry, researchers, governments, regulatory bod-
ies, hospitals and insurers.
2. Inclusion of central review processes for site-specific authorisations within clusters.
3. Development of overarching contracts for the tele-trial model between sites within clusters 
in order to simplify the contract processes at local, state and national levels.
4. Development of a pre-accreditation process where the focus is on the capability of the site 
and the investigator at the satellite, well ahead of any trial. Once pre-accredited, a satellite 
should be able to recruit to any trial immediately or at short notice, if they have a candidate 
case. A pre-accredited satellite could then recruit to more than one primary site, provided 
that the trial of interest has been approved by the primary site governance and ethical 
approval processes. Any primary sites could pre-accredit a number of satellite sites even 
though different sites may be part of a cluster at different times.
5. Provision of incentives by funding bodies and government and non-government organisa-
tions for hospitals, industry or trials groups to accommodate innovative models such as 
the Australasian Tele-trial model in their trial protocols to improve access to clinical trials 
for rural and regional cancer patients.
6. Exploration of the feasibility of adopting remote monitoring systems by Sponsors and au-
diting authorities.
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